These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24893628)

  • 1. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.
    Soong RS; Song L; Trieu J; Knoff J; He L; Tsai YC; Huh W; Chang YN; Cheng WF; Roden RB; Wu TC; Trimble CL; Hung CF
    Clin Cancer Res; 2014 Nov; 20(21):5456-67. PubMed ID: 24893628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
    Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
    Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
    Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
    Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
    van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
    Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.
    Esquerré M; Bouillette-Marussig M; Goubier A; Momot M; Gonindard C; Keller H; Navarro A; Bissery MC
    PLoS One; 2017; 12(3):e0174038. PubMed ID: 28301611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination.
    Chuang CM; Monie A; Hung CF; Wu TC
    J Biomed Sci; 2010 Apr; 17(1):32. PubMed ID: 20426849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.
    Domingos-Pereira S; Decrausaz L; Derré L; Bobst M; Romero P; Schiller JT; Jichlinski P; Nardelli-Haefliger D
    Mucosal Immunol; 2013 Mar; 6(2):393-404. PubMed ID: 22968420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.
    Lee SY; Huang Z; Kang TH; Soong RS; Knoff J; Axenfeld E; Wang C; Alvarez RD; Chen CS; Hung CF; Wu TC
    J Mol Med (Berl); 2013 Oct; 91(10):1221-31. PubMed ID: 23715898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors.
    Sun Y; Peng S; Qiu J; Miao J; Yang B; Jeang J; Hung CF; Wu TC
    Gene Ther; 2015 Jul; 22(7):528-35. PubMed ID: 25786869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.
    Best SR; Peng S; Juang CM; Hung CF; Hannaman D; Saunders JR; Wu TC; Pai SI
    Vaccine; 2009 Sep; 27(40):5450-9. PubMed ID: 19622402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells.
    Choi YW; Kang MC; Seo YB; Namkoong H; Park Y; Choi DH; Suh YS; Lee SW; Sung YC; Jin HT
    Clin Cancer Res; 2016 Dec; 22(23):5898-5908. PubMed ID: 27407095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
    Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
    Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
    Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia.
    Todd RW; Steele JC; Etherington I; Luesley DM
    Gynecol Oncol; 2004 Jan; 92(1):167-74. PubMed ID: 14751153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1.
    Lasaro MO; Diniz MO; Reyes-Sandoval A; Ertl HC; Ferreira LC
    Microbes Infect; 2005 Dec; 7(15):1541-50. PubMed ID: 16213178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
    Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
    Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
    Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
    J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.